Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITCI NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/AJNJJohnson & Johnson$190.32-0.3%$179.28$140.68▼$194.40$458.40B0.48.91 million shs3.95 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+78.59%JNJJohnson & Johnson0.00%+1.02%+7.17%+15.84%+18.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/AJNJJohnson & Johnson$190.32-0.3%$179.28$140.68▼$194.40$458.40B0.48.91 million shs3.95 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+78.59%JNJJohnson & Johnson0.00%+1.02%+7.17%+15.84%+18.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITCIIntra-Cellular Therapies 2.11Hold$121.29-8.03% DownsideJNJJohnson & Johnson 2.74Moderate Buy$200.445.32% UpsideCurrent Analyst Ratings BreakdownLatest JNJ and ITCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025JNJJohnson & JohnsonArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$210.0010/15/2025JNJJohnson & JohnsonRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$174.00 ➝ $209.0010/15/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$190.0010/15/2025JNJJohnson & JohnsonStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$165.00 ➝ $190.0010/15/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$213.00 ➝ $215.0010/15/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$198.00 ➝ $204.0010/14/2025JNJJohnson & JohnsonCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/14/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$190.00 ➝ $214.0010/10/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$209.0010/10/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$176.00 ➝ $178.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44JNJJohnson & Johnson$90.63B5.06$13.08 per share14.55$29.69 per share6.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/AJNJJohnson & Johnson$14.07B$9.3520.3617.192.4025.00%32.49%13.00%N/ALatest JNJ and ITCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/14/2025Q3 2025JNJJohnson & Johnson$2.76$2.80+$0.04$2.12$23.73 billion$23.99 billion7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.73%N/A55.61%64 YearsLatest JNJ and ITCI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date10/14/2025JNJJohnson & Johnsonquarterly$1.302.72%11/25/202511/25/202512/9/20257/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITCIIntra-Cellular TherapiesN/A7.667.51JNJJohnson & Johnson0.501.010.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITCIIntra-Cellular Therapies92.33%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipITCIIntra-Cellular Therapies2.60%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableJNJ and ITCI HeadlinesRecent News About These CompaniesJohnson & Johnson's MedTech spin-off could boost focus, Bank of America says2 hours ago | proactiveinvestors.comJohnson & Johnson Stock Can Keep Rising as Strategy Pays Off...2 hours ago | marketbeat.comJohnson & Johnson (NYSE:JNJ) Price Target Raised to $215.003 hours ago | marketbeat.comBank of America Increases Johnson & Johnson (NYSE:JNJ) Price Target to $204.00October 15 at 8:49 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Q3 2025 Earnings Call TranscriptOctober 15 at 8:11 AM | insidermonkey.comJohnson & Johnson reveals 2025 sales forecast and plans for its orthopedics businessOctober 15 at 8:03 AM | fastcompany.comFBalanced Outlook on Johnson & Johnson: Hold Rating Amid Strategic Shifts and UncertaintiesOctober 15 at 7:11 AM | tipranks.comHold Recommendation for Johnson & Johnson Amid Modest Earnings Beat and Strategic Spin-Off PlansOctober 15 at 6:11 AM | tipranks.comThis 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can BuyOctober 15 at 5:50 AM | fool.comThis 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can BuyOctober 15 at 5:20 AM | fool.comJohnson & Johnson (NYSE:JNJ) S&P 500 Fund Operations StructureOctober 15 at 4:21 AM | kalkinemedia.comKUBS Maintains Johnson & Johnson (JNJ) Buy RecommendationOctober 15 at 4:21 AM | msn.comStack Financial Management Inc Sells 2,101 Shares of Johnson & Johnson $JNJOctober 15 at 4:14 AM | marketbeat.comJohnson & Johnson $JNJ Position Raised by Cypress Capital GroupOctober 15 at 4:14 AM | marketbeat.comMOKAN Wealth Management Inc. Raises Stake in Johnson & Johnson $JNJOctober 15 at 4:14 AM | marketbeat.comAllspring Global Investments Holdings LLC Buys 186,198 Shares of Johnson & Johnson $JNJOctober 15 at 4:13 AM | marketbeat.comAlmanack Investment Partners LLC. Has $1.54 Million Position in Johnson & Johnson $JNJOctober 15 at 4:13 AM | marketbeat.comMitchell Sinkler & Starr PA Sells 42,813 Shares of Johnson & Johnson $JNJOctober 15 at 4:13 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by SPC Financial Inc.October 15 at 4:13 AM | marketbeat.comMeritage Portfolio Management Has $12.36 Million Stock Position in Johnson & Johnson $JNJOctober 15 at 4:13 AM | marketbeat.comJohnson & Johnson $JNJ Shares Purchased by Cwm LLCOctober 15 at 4:06 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Why AbbVie and Johnson & Johnson Could Outperform PfizerBy Chris Markoch | October 8, 2025Johnson & Johnson Stock Can Keep Rising as Strategy Pays OffBy Thomas Hughes | October 15, 2025JNJ and ITCI Company DescriptionsIntra-Cellular Therapies NASDAQ:ITCIIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Johnson & Johnson NYSE:JNJ$190.32 -0.53 (-0.28%) As of 01:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
